Related Experiment Video
Updated: Aug 15, 2026

Multicellular Human Alveolar Model Composed of Epithelial Cells and Primary Immune Cells for Hazard Assessment
Published on: May 6, 2020
A hepatitis B vaccination programme for inner metropolitan Sydney neonates
1Department of Community Medicine, Royal Prince Alfred Hospital, Queen Elizabeth II Rehabilitation Centre, Camperdown, NSW.
Insights
A hepatitis B vaccination program achieved high compliance in a mobile urban population, with an estimated 92% of infants fully protected. This demonstrates successful vaccine delivery in a challenging demographic, crucial for public health.
Area of Science:
- Public Health
- Immunology
- Epidemiology
Background:
- Hepatitis B poses a significant public health challenge, particularly in diverse urban populations.
- Previous concerns existed regarding vaccination efficacy in mobile urban communities with high foreign-born populations.
Purpose of the Study:
- To assess the effectiveness of a hepatitis B vaccination program for high-risk infants in an urban setting.
- To evaluate vaccination compliance rates in a population with potential barriers to healthcare access.
Main Methods:
- A follow-up study of 1429 infants enrolled between September 1987 and December 1988.
- Vaccinations were administered by early childhood center nurses, with adjustments for parental reports.
- High-risk infants included neonates born to surface antigen-positive mothers, those from high-prevalence countries, Aboriginal infants, and infants of intravenous drug users.
Main Results:
- 87% of infants received two doses, and 73% received three doses of the hepatitis B vaccine.
- An estimated 92% of infants achieved full protection when including vaccinations reported by parents.
- The program demonstrated high compliance rates in a population previously considered difficult for vaccine delivery.
Conclusions:
- The hepatitis B vaccination program was effective in achieving high compliance among high-risk infants in a mobile urban population.
- Current state policies for hepatitis B vaccination may not be optimal for reducing surface antigen carriers in the community.
- Successful implementation highlights the potential for targeted vaccination strategies in diverse urban settings.
Unlabelled:
OBJECTIVE; To review the effectiveness of a hepatitis B vaccination programme for high risk infants within a mobile urban population.
Design:
A follow-up study of 1429 infants enrolled consecutively in the programme from September 1987 to December 1988.
Setting:
The programme was established in early childhood centres within inner metropolitan Sydney, an area where 30% of residents were born in non-English speaking countries and where doubts had previously been expressed about the efficacy of vaccination.
Participants:
Neonates born to mothers who were surface antigen positive, born in selected countries with a 5% prevalence of surface antigen carriage, Aboriginal or intravenous drug users.
Outcome Measures:
Documented vaccination given by early childhood centre nurses. Some adjustment was made for parents' reports of vaccination given elsewhere.
Results:
Two vaccinations were given to 87% and three to 73% of these infants. If we include vaccinations apparently given elsewhere we estimate that 92% may have been fully protected.
Conclusion:
The programme produced high rates of compliance with vaccinations within a population where the delivery of such a service was thought to be difficult. Experience with the current State policy for hepatitis B vaccination indicates that it may not optimally reduce the pool of surface antigen carriers within our community.
Related Concept Videos
Vaccinations
Development of Immunocompetence
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
Respiratory Syncytial Virus Disease
Hepatitis
Viral Hepatitis I: Introduction

